Which has preferable earnings and valuation, ENGN or SCYX?

SCYNEXIS has higher revenue and earnings than enGene. SCYNEXIS is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.25 N/A SCYNEXIS $20.60M 1.21 -$8.61M -$3.84 N/A

Is ENGN or SCYX more profitable?

enGene has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. enGene's return on equity of -55.83% beat SCYNEXIS's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -55.83% -45.74% SCYNEXIS -41.79% -57.16% -39.48%

Do analysts recommend CYPH or SCYX?

SCYNEXIS has a consensus target price of $24.00, suggesting a potential upside of 439.33%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend AIFC or SCYX?

SCYNEXIS has a consensus price target of $24.00, suggesting a potential upside of 439.33%. Given SCYNEXIS's stronger consensus rating and higher possible upside, analysts plainly believe SCYNEXIS is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, AIFC or SCYX?

SCYNEXIS has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 3.70 -$344.51M N/A N/A SCYNEXIS $20.60M 1.21 -$8.61M -$3.84 N/A

Is AIFC or SCYX more profitable?

SCYNEXIS has a net margin of -41.79% compared to ALT5 Sigma's net margin of -2,483.94%. SCYNEXIS's return on equity of -57.16% beat ALT5 Sigma's return on equity. Company Net Margins Return on Equity Return on Assets ALT5 Sigma -2,483.94% -68.25% -62.43% SCYNEXIS -41.79% -57.16% -39.48%

SCYNEXIS (SCYX) Competitors

$4.45 -0.26 (-5.52%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$4.48 +0.03 (+0.58%)

As of 06/8/2026 06:26 PM Eastern

Compare

SCYX vs. ONCY, ENGN, CYPH, AIFC, and RANI

Should you buy SCYNEXIS stock or one of its competitors? MarketBeat compares SCYNEXIS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SCYNEXIS include Oncolytics Biotech (ONCY), enGene (ENGN), Cypherpunk Technologies (CYPH), ALT5 Sigma (AIFC), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical products" industry.

How does SCYNEXIS compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

SCYNEXIS has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
SCYNEXIS	$20.60M	1.21	-$8.61M	-$3.84	N/A

In the previous week, Oncolytics Biotech had 2 more articles in the media than SCYNEXIS. MarketBeat recorded 2 mentions for Oncolytics Biotech and 0 mentions for SCYNEXIS. Oncolytics Biotech's average media sentiment score of 0.26 beat SCYNEXIS's score of 0.00 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Oncolytics Biotech	Neutral
SCYNEXIS	Neutral

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 4.1% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oncolytics Biotech presently has a consensus target price of $8.50, suggesting a potential upside of 911.90%. SCYNEXIS has a consensus target price of $24.00, suggesting a potential upside of 439.33%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Oncolytics Biotech is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oncolytics Biotech has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Oncolytics Biotech has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Summary

Oncolytics Biotech beats SCYNEXIS on 9 of the 16 factors compared between the two stocks.

How does SCYNEXIS compare to enGene?

enGene (NASDAQ:ENGN) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

SCYNEXIS has higher revenue and earnings than enGene. SCYNEXIS is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
SCYNEXIS	$20.60M	1.21	-$8.61M	-$3.84	N/A

enGene has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. enGene's return on equity of -55.83% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
SCYNEXIS	-41.79%	-57.16%	-39.48%

enGene presently has a consensus price target of $12.68, suggesting a potential upside of 668.60%. SCYNEXIS has a consensus price target of $24.00, suggesting a potential upside of 439.33%. Given enGene's stronger consensus rating and higher probable upside, equities research analysts plainly believe enGene is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

64.2% of enGene shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

enGene has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

In the previous week, enGene had 12 more articles in the media than SCYNEXIS. MarketBeat recorded 12 mentions for enGene and 0 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.00 beat enGene's score of -0.06 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Overall Sentiment
enGene	Neutral
SCYNEXIS	Neutral

Summary

enGene beats SCYNEXIS on 10 of the 15 factors compared between the two stocks.

How does SCYNEXIS compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by insiders. Comparatively, 4.1% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Cypherpunk Technologies' average media sentiment score of 0.00 equaled SCYNEXIS'saverage media sentiment score.

Company	Overall Sentiment
Cypherpunk Technologies	Neutral
SCYNEXIS	Neutral

SCYNEXIS has a consensus target price of $24.00, suggesting a potential upside of 439.33%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cypherpunk Technologies has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Cypherpunk Technologies has higher earnings, but lower revenue than SCYNEXIS. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
SCYNEXIS	$20.60M	1.21	-$8.61M	-$3.84	N/A

Cypherpunk Technologies has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Cypherpunk Technologies' return on equity of -48.33% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Summary

SCYNEXIS beats Cypherpunk Technologies on 9 of the 13 factors compared between the two stocks.

How does SCYNEXIS compare to ALT5 Sigma?

ALT5 Sigma (NASDAQ:AIFC) and SCYNEXIS (NASDAQ:SCYX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by company insiders. Comparatively, 4.1% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, ALT5 Sigma's average media sentiment score of 0.00 equaled SCYNEXIS'saverage media sentiment score.

Company	Overall Sentiment
ALT5 Sigma	Neutral
SCYNEXIS	Neutral

SCYNEXIS has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	3.70	-$344.51M	N/A	N/A
SCYNEXIS	$20.60M	1.21	-$8.61M	-$3.84	N/A

SCYNEXIS has a net margin of -41.79% compared to ALT5 Sigma's net margin of -2,483.94%. SCYNEXIS's return on equity of -57.16% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
SCYNEXIS	-41.79%	-57.16%	-39.48%

ALT5 Sigma has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

SCYNEXIS has a consensus price target of $24.00, suggesting a potential upside of 439.33%. Given SCYNEXIS's stronger consensus rating and higher possible upside, analysts plainly believe SCYNEXIS is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

SCYNEXIS beats ALT5 Sigma on 9 of the 12 factors compared between the two stocks.

How does SCYNEXIS compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

SCYNEXIS has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	63.81	-$29.67M	-$0.41	N/A
SCYNEXIS	$20.60M	1.21	-$8.61M	-$3.84	N/A

In the previous week, Rani Therapeutics had 8 more articles in the media than SCYNEXIS. MarketBeat recorded 8 mentions for Rani Therapeutics and 0 mentions for SCYNEXIS. Rani Therapeutics' average media sentiment score of 1.00 beat SCYNEXIS's score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Rani Therapeutics	Positive
SCYNEXIS	Neutral

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by insiders. Comparatively, 4.1% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rani Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Rani Therapeutics presently has a consensus target price of $8.75, indicating a potential upside of 942.16%. SCYNEXIS has a consensus target price of $24.00, indicating a potential upside of 439.33%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Rani Therapeutics is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rani Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Summary

Rani Therapeutics beats SCYNEXIS on 9 of the 16 factors compared between the two stocks.

Get SCYNEXIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCYX vs. The Competition

Export

Metric	SCYNEXIS	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$26.30M	$2.96B	$6.48B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.58%
P/E Ratio	-1.16	17.68	23.69	23.74
Price / Sales	1.21	302.68	513.81	108.85
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	0.49	3.83	10.41	6.78
Net Income	-$8.61M	$75.85M	$3.57B	$337.51M
7 Day Performance	-12.75%	-2.00%	0.28%	-2.34%
1 Month Performance	-39.25%	-5.85%	3.27%	1.88%
1 Year Performance	-35.32%	14.03%	22.25%	25.55%

SCYNEXIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCYX SCYNEXIS	1.6119 of 5 stars	$4.45 -5.5%	$24.00 +439.3%	-39.4%	$26.30M	$20.60M	N/A	60
ONCY Oncolytics Biotech	3.7687 of 5 stars	$0.93 -12.1%	$8.50 +812.0%	+133.3%	$124.13M	N/A	N/A	30	High Trading Volume
ENGN enGene	4.0974 of 5 stars	$1.75 -2.0%	$12.68 +626.8%	-56.3%	$123.92M	N/A	N/A	31	Upcoming Earnings
CYPH Cypherpunk Technologies	0.4306 of 5 stars	$1.05 -7.1%	N/A	+80.2%	$120.30M	N/A	N/A	40	Gap Up
AIFC ALT5 Sigma	0.1086 of 5 stars	$0.86 +1.1%	N/A	-93.6%	$119.00M	$24.70M	N/A	170	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCYX) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SCYNEXIS (SCYX) Competitors

SCYX vs. ONCY, ENGN, CYPH, AIFC, and RANI

How does SCYNEXIS compare to Oncolytics Biotech?

Summary

How does SCYNEXIS compare to enGene?

Summary

How does SCYNEXIS compare to Cypherpunk Technologies?

Summary

How does SCYNEXIS compare to ALT5 Sigma?

Summary

How does SCYNEXIS compare to Rani Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX vs. The Competition

SCYNEXIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SCYNEXIS (SCYX) Competitors

SCYX vs. ONCY, ENGN, CYPH, AIFC, and RANI

How does SCYNEXIS compare to Oncolytics Biotech?

Which has better earnings & valuation, ONCY or SCYX?

Does the media refer more to ONCY or SCYX?

Do institutionals and insiders hold more shares of ONCY or SCYX?

Do analysts prefer ONCY or SCYX?

Which has more volatility & risk, ONCY or SCYX?

Is ONCY or SCYX more profitable?

Summary

How does SCYNEXIS compare to enGene?

Which has preferable earnings and valuation, ENGN or SCYX?

Is ENGN or SCYX more profitable?

Do analysts prefer ENGN or SCYX?

Do insiders and institutionals hold more shares of ENGN or SCYX?

Which has more risk and volatility, ENGN or SCYX?

Does the media favor ENGN or SCYX?

Summary

How does SCYNEXIS compare to Cypherpunk Technologies?

Do insiders & institutionals believe in CYPH or SCYX?

Does the media refer more to CYPH or SCYX?

Do analysts recommend CYPH or SCYX?

Which has more volatility & risk, CYPH or SCYX?

Which has better valuation & earnings, CYPH or SCYX?

Is CYPH or SCYX more profitable?

Summary

How does SCYNEXIS compare to ALT5 Sigma?

Do institutionals and insiders believe in AIFC or SCYX?

Does the media refer more to AIFC or SCYX?

Which has preferable earnings and valuation, AIFC or SCYX?

Is AIFC or SCYX more profitable?

Which has more risk and volatility, AIFC or SCYX?

Do analysts recommend AIFC or SCYX?

Summary

How does SCYNEXIS compare to Rani Therapeutics?

Which has higher valuation & earnings, RANI or SCYX?

Does the media refer more to RANI or SCYX?

Do institutionals and insiders have more ownership in RANI or SCYX?

Is RANI or SCYX more profitable?

Do analysts prefer RANI or SCYX?

Which has more volatility & risk, RANI or SCYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX vs. The Competition

SCYNEXIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools